RXRX
Price:
$5.92
Market Cap:
$1.63B
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; ...[Read more]
Industry
Biotechnology
IPO Date
2021-04-16
Stock Exchange
NASDAQ
Ticker
RXRX
According to Recursion Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -79.48%. This represents a change of 293.58% compared to the average of -20.19% of the last 4 quarters.
The mean historical ROE of Recursion Pharmaceuticals, Inc. over the last ten years is -11.99%. The current -79.48% ROE has changed 562.80% with respect to the historical average. Over the past ten years (40 quarters), RXRX's ROE was at its highest in in the March 2021 quarter at 13.18%. The ROE was at its lowest in in the March 2020 quarter at -23.98%.
Average
-11.99%
Median
-32.80%
Minimum
-70.79%
Maximum
50.32%
Discovering the peaks and valleys of Recursion Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 50.26%
Maximum Annual ROE = 50.32%
Minimum Annual Increase = -176.99%
Minimum Annual ROE = -70.79%
Year | ROE | Change |
---|---|---|
2023 | -70.79% | 43.64% |
2022 | -49.28% | 50.26% |
2021 | -32.80% | -176.99% |
2020 | 42.60% | -15.33% |
The current ROE of Recursion Pharmaceuticals, Inc. (RXRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-50.96%
5-year avg
-11.99%
10-year avg
-11.99%
Recursion Pharmaceuticals, Inc.’s ROE is greater than Absci Corporation (-44.24%), greater than Affimed N.V. (-155.57%), greater than Sana Biotechnology, Inc. (-71.60%), greater than Relay Therapeutics, Inc. (-43.66%), greater than Immix Biopharma, Inc. (-86.48%), less than CNS Pharmaceuticals, Inc. (428.91%), greater than Hepion Pharmaceuticals, Inc. (-328.66%), greater than Freeline Therapeutics Holdings plc (-110.68%), less than AVROBIO, Inc. (29.68%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Enveric Biosciences, Inc. (-234.16%), greater than CohBar, Inc. (-55.32%), less than Ocean Biomedical, Inc. (567.07%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Inozyme Pharma, Inc. (-68.93%), greater than VectivBio Holding AG (-56.92%),
Company | ROE | Market cap |
---|---|---|
-44.24% | $456.50M | |
-155.57% | $57.26M | |
-71.60% | $1.12B | |
-43.66% | $835.47M | |
-86.48% | $54.08M | |
428.91% | $4.60M | |
-328.66% | $4.20M | |
-110.68% | $28.28M | |
29.68% | $5.24M | |
2.18% | $188.18K | |
-234.16% | $4.53M | |
-55.32% | $1.25M | |
567.07% | $33.96M | |
-122.70% | $1.25B | |
-24.63% | $133.38M | |
32.93% | $109.78M | |
-68.93% | $312.42M | |
-56.92% | $1.06B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Recursion Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Recursion Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Recursion Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Recursion Pharmaceuticals, Inc. (RXRX)?
What is the highest ROE for Recursion Pharmaceuticals, Inc. (RXRX)?
What is the 3-year average ROE for Recursion Pharmaceuticals, Inc. (RXRX)?
What is the 5-year average ROE for Recursion Pharmaceuticals, Inc. (RXRX)?
How does the current ROE for Recursion Pharmaceuticals, Inc. (RXRX) compare to its historical average?